Company of the week: Hemab Therapeutics
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Multiple Royalty Streams on a Single Drug: Practical Realities
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Royalty Stream Sales and Buybacks in Pharma Financing
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
China's Venture Capital Landscape in 2025 – Slump and Retreat
China's biotech venture capital (VC) sector in 2025 is recovering from a deep slump. After peaking at $15.
The Weekly Term Sheet (44)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Tax-Neutral Demerger - A case study
DISCLAIMER
This article is provided for informational and educational purposes only. It does not constitute legal, financial, tax, or investment
Fund of the Week: Curie.Bio
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Company of the week: Elevara Medicines
Company Overview and Corporate Structure
Elevara Medicines Ltd. is a London-based clinical-stage biotechnology company focused on innovative therapies for rheumatoid
Bankrupt Biotech Royalty Auctions: Navigating Royalty Sales
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Royalties Unstacked: Allocating the Proceeds in Combination Therapies
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
